[HTML][HTML] Cost-effectiveness of direct non-vitamin K oral anticoagulants versus vitamin K antagonists for the management of patients with non-valvular atrial fibrillation …
V Lorenzoni, S Pirri, G Turchetti - Clinical drug investigation, 2021 - Springer
Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation …
V Lorenzoni, S Pirri, G Turchetti - Clinical Drug Investigation, 2021 - europepmc.org
Methods A Markov model simulating the lifetime course of patients diagnosed with non-
valvular AF was used to evaluate the cost-effectiveness of DOACs (ie, rivaroxaban …
valvular AF was used to evaluate the cost-effectiveness of DOACs (ie, rivaroxaban …
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation …
V Lorenzoni, S Pirri, G Turchetti - CLINICAL DRUG INVESTIGATION, 2021 - iris.sssup.it
Background and objective: The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation …
V Lorenzoni, S Pirri, G Turchetti - Clinical drug …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
[HTML][HTML] Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial …
V Lorenzoni, S Pirri, G Turchetti - Clinical Drug Investigation, 2021 - ncbi.nlm.nih.gov
Methods A Markov model simulating the lifetime course of patients diagnosed with non-
valvular AF was used to evaluate the cost-effectiveness of DOACs (ie, rivaroxaban …
valvular AF was used to evaluate the cost-effectiveness of DOACs (ie, rivaroxaban …
Cost‑Effectiveness of Direct Non‑Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non‑Valvular Atrial Fibrillation …
V Lorenzoni, S Pirri, G Turchetti - Clinical Drug Investigation, 2021 - search.proquest.com
Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
[PDF][PDF] Cost‑Effectiveness of Direct Non‑Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non‑Valvular Atrial …
V Lorenzoni, S Pirri, G Turchetti - 2021 - researchgate.net
Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …